| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 12, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 12, 2024 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2024 | Sector Outperform | Scotiabank | |
| 7/26/2024 | $3.00 | Buy | Craig Hallum |
| 5/13/2024 | $2.80 | Buy | TD Cowen |
| 5/3/2024 | $3.00 | Buy | Lake Street |
| 11/17/2021 | $21.00 → $11.00 | Overweight → Equal-Weight | Morgan Stanley |
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. "The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals - driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation
LOUISVILLE, Colo., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will participate in three upcoming investor conferences: Craig-Hallum 15th Annual Alpha Select Conference1x1 MeetingsDate: Tuesday, November 19, 2024Location: New York, NY Wolfe Research Healthcare Conference 20241x1 MeetingsDate: Wednesday, November 20, 2024Location: New York, NY Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum Presentation and 1x1 MeetingsPresentation Date and Time: Thursday, November 21, 2024 at 1
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion
Scotiabank initiated coverage of Biodesix with a rating of Sector Outperform
Craig Hallum initiated coverage of Biodesix with a rating of Buy and set a new price target of $3.00
TD Cowen initiated coverage of Biodesix with a rating of Buy and set a new price target of $2.80
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced the appointment of Lawrence (Lair) T. Kennedy, Jr. to the Company's Board of Directors (Board) and Audit Committee of the Board effective January 3, 2023. Mr. Kennedy brings to Biodesix more than 20 years of broad operating, corporate finance, company creation and investment experience with a specific focus in the healthcare industry. "We are delighted to welcome Lair to Biodesix's Board of Directors," said Scott Hutton, Chief Executive Officer of Biodesix. "He brings a wealth of business experience with a strong background in healthcare and diagnostics. We look fo
Biodesix, Inc. (NASDAQ:BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced the appointment of Dr. Jon Faiz Kayyem to the company's board of directors. Dr. Kayyem's diverse career spans more than 20 years and includes experience in academia, lean startups, and Fortune 100 companies. He has served in various leadership positions throughout his career including numerous roles at GenMark Diagnostics, including Founder, CEO and President, Chief Scientific Officer, Senior Vice President of Research and Development. Prior to his work at GenMark Diagnostics, Dr. Kayyem served as Director and Founder of Calimmune and was Vice President of Life Sciences a
TD Cowen analyst Dan Brennan initiates coverage on Biodesix (NASDAQ:BDSX) with a Buy rating and announces Price Target of $2.8.
Biodesix (NASDAQ:BDSX) reported quarterly losses of $(0.14) per share which met the analyst consensus estimate. This is a 41.67 percent increase over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $14.818 million which beat the analyst consensus estimate of $14.180 million by 4.50 percent. This is a 63.63 percent increase over sales of $9.056 million the same period last year.
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
SC 13G/A - BIODESIX INC (0001439725) (Subject)
SC 13G - BIODESIX INC (0001439725) (Subject)
SC 13D/A - BIODESIX INC (0001439725) (Subject)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
4 - BIODESIX INC (0001439725) (Issuer)
EFFECT - BIODESIX INC (0001439725) (Filer)
EFFECT - BIODESIX INC (0001439725) (Filer)
424B3 - BIODESIX INC (0001439725) (Filer)
Q3 2024 revenue grew 35% over Q3 2023 to $18.2 million; Q3 2024 gross profit margin of 77.0%, up from 76.1% in Q3 2023; Q3 2024 Net loss improved by 6% compared to Q3 2023; Conference Call and Webcast Today at 8:30 a.m. ET LOUISVILLE, Colo., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2024. "The Biodesix team is pleased to report another solid quarter focused on executing and delivering on our three main goals - driving revenue growth through the adoption of our lung diagnostic tests and biopharma services, continued implementation
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that it will release financial results for the third quarter ended September 30, 2024 before the start of trading on Friday, November 1. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 8:30 a.m. Eastern Time on the same day. Listeners can register for the webcast via this link. Analysts who wish to participate in the question and answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion
Q2 2024 revenue grew 51% over Q2 2023 to $17.9 million; Q2 2024 gross profit margin of 78.4%, a 5.7% improvement from Q2 2023; Raises full-year 2024 revenue guidance to $70-72 million from $65-68 million; Q2 24 Net loss, including certain non-cash items, and Adjusted EBITDA improved by 19% and 38% over Q2 2023; Conference Call and Webcast Today at 4:30 p.m. ET Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2024. "The second quarter marks sustained excellence in our execution, resulting in outstanding revenue growth coupled with consistently strong gross margins, and c